The impact of Cysteine-Rich Intestinal Protein 1 (CRIP1) in human breast cancer

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Ludyga, Natalie ^a   Englert, Sonja ^a   Pflieger, Kerstin ^a   Rauser, Sandra ^a   Braselmann, Herbert ^a   Walch, Axel ^a   Auer, Gert ^b   Höfler, Heinz ^a,c   Aubele, Michaela ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; CRIP1; ERB B2; HER2; Invasion; Prognosis; Proliferation; RNA interference; RNAi; Tumorigenesis

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYSTEINE RICH INTESTINAL PROTEIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TUMOR MARKER; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR INVASION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE SILENCING; HUMANS; LIM DOMAIN PROTEINS; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 84875911746     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-28     Document Type: Article

References (40)

1. Lund MJ, Butler EN, Bumpers HI, Okoli J. High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008, 113:608-615. 10.1002/cncr.23569, 18484596.
2. Bauer KR, Brown M, Creass RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728. 10.1002/cncr.22618, 17387718.
3. Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003, 22:6570-6578. 10.1038/sj.onc.1206779, 14528282.
4. Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, Jones A, Simpson P, Harris RA, Jat PS, Neville AM, Reis LF, Lakhani SR, O'Hare MJ. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 2003, 22:2680-2688. 10.1038/sj.onc.1206349, 12730682.
5. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-744.
6. Slamon DJ. Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest 1990, 8:253. 10.3109/07357909009017573, 1976032.
7. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sqroi DC. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003, 100:5974-5979. 10.1073/pnas.0931261100, 156311, 12714683.
8. Chen Y, Miller C, Mosher R, Zhao X, Deeds J, Morrissey M, Bryant B, Yang D, Meyer R, Cronin F, Gostout BS, Smith-McCune K, Schlegel R. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res 2003, 63:1927-1935.
9. Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJ, Ahmed A, Masters JR. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007, 26:6560-6565. 10.1038/sj.onc.1210472, 17486081.
10. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 2002, 160:1745-1754. 10.1016/S0002-9440(10)61121-2, 1850868, 12000726.
11. Groene J, Mansmann U, Meister R, Staub E, Roepcke S, Heinze M, Klaman I, Brümmendorf T, Hermann K, Loddenkemper C, Pilarsky C, Mann B, Adams HP, Buhr HJ, Rosenthal A. Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III. Int J Cancer 2006, 119:1829-1836. 10.1002/ijc.22027, 16721809.
12. Wilson KS, Roberts H, Leek R, Harris AL, Geradts J. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol 2002, 161:1171-1185. 10.1016/S0002-9440(10)64394-5, 1867314, 12368191.
13. Rauser S, Marquardt C, Balluff B, Deininger SO, Albers C, Belau E, Hartmer R, Suckau D, Specht K, Ebert MP, Schmitt M, Aubele M, Höfler H, Walch A. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res 2010, 9:1854-1863. 10.1021/pr901008d, 20170166.
14. Balluff B, Rauser S, Meding S, Elsner M, Schöne C, Feuchtinger A, Schuhmacher C, Novotny A, Jütting U, Maccarrone G, Sarioglu H, Ueffing M, Braselmann H, Zitzelsberger H, Schmid RM, Höfler H, Ebert MP, Walch A. MALDI Imaging Identifies Prognostic Seven-Protein Signature of Novel Tissue Markers in Intestinal-Type Gastric Cancer. Am J Pathol 2011, 179:2720-2729. 10.1016/j.ajpath.2011.08.032, 3260837, 22015459.
15. Baumhoer D, Elsner M, Smida J, Zillmer S, Rauser S, Schoene C, Balluff B, Bielack S, Jundt G, Walch A, Nathrath M. CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients. Oncotarget 2011, 2:970-975. 3282102, 22202598.
16. Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res 2007, 67:4199-4209. 10.1158/0008-5472.CAN-06-3409, 17483331.
17. Songyang Z, Baltimore D, Cantley LC, Kaplan DR, Franke TF. Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci U S A 1997, 94:11345-11350. 10.1073/pnas.94.21.11345, 23462, 9326612.
18. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000, 20:5010-5018. 10.1128/MCB.20.14.5010-5018.2000, 85951, 10866658.
19. Liu L, Gao Y, Qiu H, Miller WT, Poli V, Reich NC. Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 2006, 25:4904-4912. 10.1038/sj.onc.1209501, 16568091.
20. Birkenmeier EH, Gordon JI. Developmental regulation of a gene that encodes a cysteine-rich intestinal protein and maps near the murine immunoglobulin heavy chain locus. Proc Natl Acad Sci U S A 1986, 83:2516-2520. 10.1073/pnas.83.8.2516, 323329, 3085096.
21. Hao J, Serohijos AW, Newton G, Tassone G, Wang Z, Sgroi DC, Dokholyan NV, Basilion JP. Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers. PLoS Comput Biol 2008, 4:e1000138. 10.1371/journal.pcbi.1000138, 2453235, 18670594.
22. Jurata LW, Kenny DA, Gill GN. Nuclear LIM interactor, a rhombotin and LIM homeodomain interacting protein, is expressed early in neuronal development. Proc Natl Acad Sci U S A 1996, 93:11693-11698. 10.1073/pnas.93.21.11693, 38120, 8876198.
23. Khoo C, Blanchard RK, Sullivan VK, Cousins RJ. Human cysteine-rich intestinal protein: cDNA cloning and expression of recombinant protein and identification in human peripheral blood mononuclear cells. Protein Expr Purif 1997, 9:379-387. 10.1006/prep.1996.0709, 9126610.
24. Lanningham-Foster L, Green CL, Langkamp-Henken B, Davis BA, Nguyen KT, Bender BS, Cousins RJ. Overexpression of CRIP in transgenic mice alters cytokine patterns and the immune response. Am J Physiol Endocrinol Metab 2002, 282:E1197-1203.
25. Cousins RJ, Lanningham-Foster L. Regulation of cysteine-rich intestinal protein, a zinc finger protein, by mediators of the immune response. J Infect Dis 2000, 182(Suppl 1):81-84.
26. Klein A, Olendrowitz C, Schmutzler R, Hampl J, Schlag PM, Maass N, Arnold N, Wessel R, Ramser J, Meindl A, Scherneck S, Seitz S. Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett 2009, 276:212-220. 10.1016/j.canlet.2008.11.017, 19114293.
27. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006, 24:2261-2267. 10.1200/JCO.2005.03.8802, 16636340.
28. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392. 10.1126/science.1067100, 11923519.
29. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 1990, 29:5783-5789. 10.1021/bi00476a020, 2383557.
30. Latonen L, Järvinen PM, Laiho M. Cytoskeleton-interacting LIM-domain protein CRP1 suppresses cell proliferation and protects from stress-induced cell death. Exp Cell Res 2008, 314:738-747. 10.1016/j.yexcr.2007.11.024, 18177859.
31. Ikeda O, Miyasaka Y, Sekine Y, Mizushima A, Muromoto R, Nanbo A, Yoshimura A, Matsuda T. STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation. Biochem Biophys Res Commun 2009, 384:71-75. 10.1016/j.bbrc.2009.04.076, 19393627.
32. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999, 96:4240-4245. 10.1073/pnas.96.8.4240, 33561, 10200246.
33. Franke TF, Cantley LC. Apoptosis. A Bad kinase makes good. Nature 1997, 390:116-117. 10.1038/36442, 9367147.
34. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1992, 61:441-470. 10.1146/annurev.bi.61.070192.002301, 1497317.
35. Watanabe N, Broome M, Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 1995, 14:1878-1891. 398287, 7743995.
36. Jeschke J, Van Neste L, Glöckner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, Chan TA, Cope L, Hooker CM, Schuebel KE, Gabrielson E, Winterpacht A, Baylin SB, Herman JG, Ahuja N. Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 2012, 7:701-709. 10.4161/epi.20445, 22647880.
37. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
38. Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H, Fornander T, Bartlett JM. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 2007, 96:801-807. 10.1038/sj.bjc.6603613, 2360069, 17299391.
39. Ludyga N, Anastasov N, Gonzalez-Vasconcellos I, Ram M, Höfler H, Aubele M. Impact of Protein Tyrosine Kinase 6 (PTK6) on Human Epidermal Growth Factor Receptor (HER) Signalling in Breast Cancer. Mol Biosyst 2011, 7:1603-1612. 10.1039/c0mb00286k, 21380407.
40. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007, 2:329-333.